



Press release |

IBA Dosimetry Achieves 1000th Clinical MatriXX User Milestone

Advanced dose detector technology with COMPASS Patient Dose Analysis improves treatment accuracy and safety in radiation therapy

Schwarzenbruck, Germany, October 27, 2010 – [IBA Dosimetry](#), member of [IBA Group](#), today announces the milestone of its 1,000th clinical [MatriXX Detector](#) user. The MatriXX Detectors (I^mRT MatriXX and MatriXX Evolution) are two-dimensional ionization chamber arrays to verify absorbed dose versus plan, especially in Intensity-Modulated Radiation Therapy (IMRT) and rotational treatments.

Using Pixel Ionization Chamber (PIC) technology, the MatriXX Detector has advantages for precise and reliable digital treatment verification. Compared to diode-based solutions, PIC technology provides the lowest dependency on angle and energy changes for consistent measurement data, and long-term stability for data consistency over time.

MatriXX technology is designed to be used with IBA's [OmniPro-I^mRT](#) software for complete plan verification and QA of IMRT and rotational treatments, or unique [COMPASS Patient Dose Analysis](#) software, which verifies and displays dosage independently in each patient's anatomy to detect potential errors on a clinical level instead of a phantom and to save lives.

"When planning and verifying individualized treatment plans, the distinct advantages of our MatriXX Detector provides our radiation therapy team the data quality – and the confidence – to know that we are providing our patients with the most accurate and effective treatment possible," said Dr. Domenico Delli Carpini, medical physicist at Greenwich Hospital's Bendheim Cancer Center. "Since beginning to use the MatriXX Detector with COMPASS Patient Dose Analysis, the solution has quickly grown to play an integral role in Greenwich Hospital's approach to deliver radiation therapy safely, efficiently and patient-centered."

"Radiation therapy is advancing every day. While treatment accuracy continues to improve, healthcare providers are challenged to address this increasing complexity while providing precise and safe patient treatments," said Ralf Schira, vice president, marketing at IBA Dosimetry. "The 1000th MatriXX detector clinical implementation is a testimonial to our customers who provide cutting-edge treatments with the highest levels of accuracy and patient safety."

Since its launch in June 2005, MatriXX has evolved into the newest version MatriXX Evolution, an advanced solution for verifying rotational treatments like RapidArc (TM) or VMAT. Studies have shown that MatriXX provides the highest spacial resolution of any dedicated rotational QA solution as well as the market's fastest data sampling rate for verification accuracy, especially in complex treatments with rapidly changing fields and doses.

###

About IBA Dosimetry and IBA group

IBA Dosimetry offers a full range of innovative solutions for radiotherapy, radiodiagnostics, calibration service and imaging markers. Its measuring instruments and software enable medical physicists and radiologists to perform the necessary quality assurance and calibration procedures.



IBA develops and markets leading-edge technologies, pharmaceuticals and tailor-made solutions for healthcare with a focus on cancer diagnosis and therapy. Leveraging on its scientific expertise, IBA is also active in the field of industrial sterilization and ionization. Listed on the pan-European stock exchange EURONEXT, IBA is included in the BelMid Index. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

Please visit www.iba-dosimetry.com and www.iba-worldwide.com for more information about IBA Dosimetry and IBA group.

Media contact:

Ralf Schira, VP Marketing, IBA Dosimetry

Tel.: +49 9128 607 0 / Email: ralf.schira@iba-group.com